{"id":"intravenous-scopolamine-hydrobromide","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Urinary retention"}]},"_chembl":{"chemblId":"CHEMBL2251240","moleculeType":"Small molecule","molecularWeight":"438.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Scopolamine competitively antagonizes acetylcholine at muscarinic receptors in the central and peripheral nervous system. This anticholinergic activity reduces gastric secretions, decreases smooth muscle contractions in the GI tract, and depresses the vomiting center and vestibular apparatus in the brain, making it effective for preventing nausea and vomiting associated with motion sickness and postoperative states.","oneSentence":"Scopolamine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce secretions and motion-induced nausea.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:56.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of nausea and vomiting associated with motion sickness"},{"name":"Prevention of postoperative nausea and vomiting"},{"name":"Preoperative medication to reduce secretions"}]},"trialDetails":[{"nctId":"NCT04823065","phase":"PHASE1, PHASE2","title":"4FMFES-PET Imaging of Endometrial and Ovarian Cancers","status":"COMPLETED","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","startDate":"2018-09-01","conditions":"Endometrial Cancer, Ovarian Cancer","enrollment":53},{"nctId":"NCT05719467","phase":"PHASE3","title":"SAINT: Safe Induction of Labor Trial","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2023-01-03","conditions":"Labor Complication, Induced; Birth, Pregnancy Related","enrollment":3000},{"nctId":"NCT03435003","phase":"PHASE4","title":"Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2017-08-28","conditions":"Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy","enrollment":83},{"nctId":"NCT02515474","phase":"NA","title":"Comparison of LCBDE vs ERCP + LC for Choledocholithiasis","status":"COMPLETED","sponsor":"Hepatopancreatobiliary Surgery Institute of Gansu Province","startDate":"2015-09-01","conditions":"Choledocholithiasis","enrollment":1000},{"nctId":"NCT03961165","phase":"PHASE3","title":"BUSCLAB - Buscopan to Prevent Slow Progress in Labor","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2019-05-25","conditions":"Labor (Obstetrics)--Complications, Labor; Prolonged, First Stage","enrollment":250},{"nctId":"NCT04349722","phase":"PHASE4","title":"The Effect of Hyoscine-N-butylbromide (HBB, Buscopan) in Augmented Labour Among Primigravidae","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2019-12-01","conditions":"Labor Long","enrollment":110},{"nctId":"NCT03055390","phase":"PHASE4","title":"Effect of Intravenous Hyoscine Butylbromide Injection on Labour in High Risk Women","status":"COMPLETED","sponsor":"Cairo University","startDate":"2017-02-11","conditions":"Vaginal Delivery","enrollment":300},{"nctId":"NCT02824679","phase":"PHASE4","title":"Effect of Intravenous Hyoscine Butylbromide Injection on First Stage Labour in Primigavidae","status":"COMPLETED","sponsor":"Ahmed M Maged, MD","startDate":"2015-07","conditions":"Vaginal Delivery","enrollment":200},{"nctId":"NCT03430362","phase":"NA","title":"Effect Of Intravenous Hyoscine -N-Butyl Bromide In Management Of Prolonged Labor In Nulliparous","status":"COMPLETED","sponsor":"Cairo University","startDate":"2018-03-02","conditions":"Prolonged Labor","enrollment":100},{"nctId":"NCT03029650","phase":"PHASE4","title":"Scopolamine Patch Pharmacokinetics in Healthy Adults","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2016-11","conditions":"Healthy","enrollment":26},{"nctId":"NCT02479581","phase":"PHASE2","title":"The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2015-07","conditions":"Valvular Heart Disease","enrollment":226},{"nctId":"NCT02557087","phase":"PHASE2","title":"Hyoscine ButylBromide for Intrapartum Analgesia","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","startDate":"2015-09","conditions":"Analgesia, Obstetrical","enrollment":104},{"nctId":"NCT02508142","phase":"PHASE4","title":"Analgesic Efficacy of Intravenous Hyoscine-N-Butylbromide (HNB) in Abdominal Colic Associated With Acute Gastroenteritis","status":"UNKNOWN","sponsor":"Kocaeli University","startDate":"2015-07","conditions":"Abdominal Cramps","enrollment":126},{"nctId":"NCT01657747","phase":"NA","title":"Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2011-11","conditions":"Ovarian Carcinoma","enrollment":350},{"nctId":"NCT02410460","phase":"NA","title":"Anesthetics in Rhytidoplasty - A Comparison Study","status":"COMPLETED","sponsor":"Mercy Facial Plastic Surgery Center","startDate":"2013-09","conditions":"Rhytidoplasty","enrollment":30},{"nctId":"NCT01281501","phase":"PHASE4","title":"Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2011-01","conditions":"Dyspepsia, Emergency, Pain","enrollment":87}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Intravenous scopolamine hydrobromide","genericName":"Intravenous scopolamine hydrobromide","companyName":"University of Iowa","companyId":"university-of-iowa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Scopolamine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce secretions and motion-induced nausea. Used for Prevention of nausea and vomiting associated with motion sickness, Prevention of postoperative nausea and vomiting, Reduction of salivary and bronchial secretions during anesthesia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}